Cognizin is a brand name for citicoline (CDP-choline), a compound your body uses to build cell membranes, including those in the brain. It is not a different chemical. It is citicoline made by a specific manufacturer and sold under a registered trademark. In the United States, citicoline is sold as a dietary supplement and is not an FDA-approved drug, so no brand of it, including Cognizin, has been shown in FDA-reviewed trials to treat any disease.
The research behind Cognizin's own marketing centers on attention in healthy people. Two small randomized trials led by McGlade found better attention-test scores in adult women at 250 and 500 mg per day, and gains in attention and psychomotor speed in adolescent males. Both McGlade trials were funded by Cognizin's manufacturer, so the results should be read with that in mind. Separately, citicoline as a compound has large negative trials in serious illness: the ICTUS trial in acute stroke (Dávalos, Lancet 2012, about 2,300 people) showed no improvement in 90-day recovery versus placebo. That negative result matters because it shows what citicoline, from any manufacturer, has not been proven to do.
Evidence at a glance
| Question | Best evidence | Tier | Bottom line |
|---|---|---|---|
| Is Cognizin different from generic citicoline? | Label and naming comparison | Label-reading topic | No. Cognizin is a brand of citicoline (CDP-choline), the same compound sold generically. |
| Does it improve attention in healthy adults? | McGlade 2012, women, 250/500 mg | T1 small, industry funded | Better attention-test scores, but Cognizin-funded and small. |
| Does it help attention in adolescents? | McGlade, adolescent males | T1 small, industry funded | Attention and psychomotor speed gains, again Cognizin-funded. |
| Does citicoline aid stroke recovery? | ICTUS, Dávalos, Lancet 2012 | T1 | No improvement in 90-day recovery versus placebo. |
| Does it treat ADHD? | No adequate trials | , | No good evidence it treats ADHD. |
| Is it safe? | Trial safety data, 250, 2,000 mg/day | T2 | Generally well tolerated; mild GI upset, headache, insomnia. |
What a brand name actually means here
Supplement marketing often makes a branded ingredient sound like a unique discovery. With Cognizin, the honest description is simpler: it is citicoline produced by a Japanese company and supplied to supplement makers, who then feature the trademark on their labels. The molecule is identical to generic citicoline and to CDP-choline. If you want a fuller explanation of that naming overlap, see our page on citicoline and CDP-choline being the same compound.
Branding can still matter for practical reasons, such as a consistent manufacturing process and dose per capsule. But it does not change what the evidence shows. When a study used generic citicoline and another used Cognizin, the compound under study was the same one.
Reading the attention trials fairly
The two McGlade trials are the studies most often cited on Cognizin packaging and websites. They were properly randomized, which is good design. But they were small, ran in healthy volunteers rather than people with a diagnosed attention disorder, and measured performance on computerized attention tests rather than real-world outcomes like school or work performance. And both were funded by Cognizin's manufacturer, which does not make the results wrong but does mean independent replication would strengthen them.
What these trials do not support is any claim about ADHD. There are no adequate trials of citicoline in ADHD, and there is no good evidence citicoline treats ADHD. Healthy-volunteer test scores cannot be stretched into a treatment claim for a diagnosed condition.
Why the stroke result belongs in this discussion
Some readers wonder why a stroke trial matters for a supplement sold for focus. The answer is that ICTUS is the largest, highest-quality randomized trial of citicoline ever run, in roughly 2,300 people. It found no improvement in 90-day recovery versus placebo, and it corrected earlier meta-analyses that had suggested benefit. That history is a useful lesson: small positive trials can add up to a misleading picture, and one large, rigorous trial can overturn it. The large COBRIT trial in traumatic brain injury (Zafonte, JAMA 2012) also found no improvement in functional or cognitive outcomes versus placebo.
You can browse the broader evidence on our citicoline hub and this brand's dedicated page at Cognizin.
Mechanism and safety in plain terms
Mechanistically, citicoline may support membrane phospholipid synthesis, which is the plausible reason researchers studied it in brain conditions at all. Neuroprotection claims, however, remain preclinical, supported by lab and animal work, not by confirmed human trials. On safety, trials using 250 to 2,000 mg per day found it generally well tolerated, with occasional mild stomach upset, headache, or insomnia. Pregnancy and breastfeeding data are lacking. One caution: citicoline may enhance levodopa effects, so people with Parkinson's disease should involve their neurologist. For general context on choosing products, see our supplements section.
Expert insight
I want readers to hold two facts at once. Cognizin is simply a brand of citicoline (CDP-choline), not a distinct or more powerful substance. The best direct evidence for the brand is two small, manufacturer-funded trials showing better attention-test scores in healthy women and adolescent males, which is suggestive but not conclusive. At the same time, the largest trials of the compound in stroke and traumatic brain injury were negative, so I do not support strong claims about brain recovery or protection. The safety profile at studied doses is reassuring, with mostly mild and occasional side effects. My advice is to weigh the modest attention evidence honestly, ignore any suggestion it treats ADHD, and discuss use with your physician if you take other medications.
Questions readers ask
Is Cognizin the same thing as citicoline?
Yes. Cognizin is a brand name; citicoline and CDP-choline are the same compound underneath.
Is Cognizin FDA-approved?
No. In the United States it is a dietary supplement, not an FDA-approved drug.
Does Cognizin treat ADHD?
No. There are no adequate trials, and there is no good evidence citicoline treats ADHD.
Who funded the attention studies?
Both McGlade trials, the adult women's study and the adolescent males' study, were Cognizin-funded.
Is it safe to take?
At 250 to 2,000 mg per day in trials it was generally well tolerated, with mild GI upset, headache, or insomnia reported. Pregnancy and breastfeeding data are lacking.
Does Cognizin help after a stroke or brain injury?
No. The large ICTUS stroke trial and the COBRIT traumatic brain injury trial both found no benefit versus placebo.
Can I take it with Parkinson's medication?
Citicoline may enhance levodopa effects. People with Parkinson's should involve their neurologist before using it.
Sources
This article draws on: McGlade 2012 (attention in adult women, Cognizin-funded); McGlade (attention and psychomotor speed in adolescent males, Cognizin-funded); ICTUS (Dávalos, Lancet 2012, acute stroke); earlier stroke meta-analyses; COBRIT (Zafonte, JAMA 2012, traumatic brain injury); and the Cochrane review by Fioravanti and Yanagi (chronic cerebrovascular cognitive decline). PMIDs are not listed until each one is confirmed on PubMed.
